abstract |
The present disclosure provides compositions and methods for treating diseases associated with CD19 expression. The invention also relates to a chimeric antigen receptor (CAR) specific for CD19, a vector encoding it, and a recombinant T cell comprising CD19CAR. The disclosure also encompasses methods of administering genetically modified T cells that express a CAR comprising a CD19 binding domain. |